NCT02998840已完成2 期
A Prospective, Vehicle Controlled, Double Blinded, Multicenter, Randomized, Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- AOBiome LLC
- 入组人数
- 132
- 试验地点
- 20
- 主要终点
- Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
研究概览
简要总结
The purpose of this study is to evaluate and compare the efficacy of B244 in treating patients with hypertension.
详细描述
This is a Prospective, Vehicle Controlled, Double Blinded, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 4 weeks vs vehicle application on BP and inflammatory biomarkers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects ≥18 years of age
- •In good general health as determined by a thorough medical history and physical examination, and vital signs
- •Clinical diagnosis of elevated Blood Pressure defined as:
- •Having systolic prehypertension measurements having systolic BP (mmHg) of 120-139 and Diastolic BP (mmHg) of 90
- •Having systolic Stage 1 hypertension measurements having systolic BP (mmHg) of 140-159 and Diastolic BP (mmHg) of 100
- •Hypertension treatment naïve patients, defined as those patients who have never been treated with antihypertensive medications or have been off any hypertensive treatment for a period of 12 weeks or longer.
- •Willing to refrain from using any antihypertensive treatments, other than the investigational product, including herbal supplements, systemic use of steroids, chronic use of NSAIDS, any antihypertensive agents, such as beta-blockers, diuretics, ACE inhibitors, CA channel blockers, Alpha blockers, Central Acting agents and vasodilators.
- •Ability to comprehend and comply with procedures
- •Agree to commit to participate in the current protocol
- •Provide written informed consent prior to any study procedure being performed (all subjects should be able to understand the informed consent form and any other documents that subjects are required to read)
排除标准
- •Pregnant and/or lactating women
- •Patients on treatment for Benign Prostatic Hyperplasia (BPH)
- •Clinically significant history of cardiovascular disease (i. e. PCI, CABG MI (if event occurred 12 months), atrial fibrillation, frequent PAC, cardiac rhythm disorder, syncope, valve repair/replacement, heart transplantation, PTA, peripheral bypass surgery, endarterectomy, unstable angina, TIA, stroke and NYHF category II, II and IV heart failure.
- •Patients with renal failure, significant kidney or renal disease defined as having creatinine level of mg/dL
- •Presence of any condition (medical, psychological, social, or geographical), actual or anticipated, that the Investigator feels would restrict or limit the patient's successful participation for the duration of the study
- •History of migraines and/or anxiety, where patient is unable to refrain from the use of beta blockers
- •History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation.
- •The participant has been previously randomized in this study
- •Subjects with clinical diagnosis of Type I Diabetes
- •Subjects with arm circumference of 42 cm
- •Any condition that would prevent the subject from participating in the trial in the opinion of the evaluation physician
- •The participant has received an investigational product within 30 days prior to randomization
- •Prior use of any product containing B244 or Nitrosomonas eutropha
- •Unable to lie flat or sit for 15 minutes
- •Concurrent participation in other trials
结局指标
主要结局
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
时间窗: Baseline-6 weeks
Safety and tolerability endpoints will consist of all treatment related adverse events reporting during the study duration.
Difference in Mean in Clinic Systolic BP Between the Active and Vehicle Groups
时间窗: Baseline-Week 4
Clinical systolic blood pressure (BP) readings were obtained at every visit using a calibrated electronic sphygmomanometer. Three measurements were taken at each visit. The average of the second and third readings was documented. Data was analyzed using mixed-effects model repeated measures (MMRM). Difference was calculated as the change from Baseline to Day 28.
次要结局
- Difference in Mean in Clinic Diastolic BP Between the Active and Vehicle Group(Baseline-Week 4)
- Difference in Mean Ambulatory Systolic and Diastolic Daytime Blood Pressure(Baseline-Week 4)
研究者
研究点 (20)
Loading locations...
相似试验
已完成
2 期
Clinical Trial in Subjects With Mild to Moderate Acne VulgarisAcne VulgarisNCT02832063AOBiome LLC372
终止
2 期
Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric PatientsCystic FibrosisNCT00060801Boehringer Ingelheim420
已完成
2 期
Safety and Efficacy of MP-424 to Treat Chronic Hepatitis CHepatitis CNCT00621296Tanabe Pharma Corporation15
已完成
2 期
Study to Evaluate the Efficacy and Safety of BIIB074 in Neuropathic Pain From Lumbosacral RadiculopathyLumbosacral RadiculopathyNCT02935608Biogen502
已完成
2 期
A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid ArthritisRheumatoid ArthritisNCT00550043Incyte Corporation50